Αρχική World News Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients with stage I to III breast cancer who were treated with 2 to 3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in longer disease-free survival (DFS) and overall survival (OS) compared to the treatment with 2 to 3 years of letrozole. The results were presented by Prof. Lucia del Mastro of the Breast Unit, Università degli Studi di Genova, Ospedale Policlinico San Martino in Genova, Italy in a proffered papers session on early stage breast cancer during the ESMO Congress 2021 (16-21 September).

Prof. del Mastro explained that benefit of extended adjuvant treatment with aromatase inhibitors in postmenopausal patients with hormone receptor (HR)-positive breast cancer treated with tamoxifen for 2 to 3 years and followed by an aromatase inhibitor for 2 to 3 years is still controversial. Breast cancer researchers from 64 Italian hospitals aimed within the Gruppo Italiano Mammella to determine whether, after 2 to 3 years of treatment with tamoxifen, 5 years of letrozole is more effective than the standard duration of letrozole treatment of 2 to 3 years.

They randomised (1:1) patients with stage I to III breast cancer who were free of recurrence after 2 to 3 years of tamoxifen, to receive 2 to 3 years (control arm) or 5 years (extended arm) of letrozole. Primary endpoint was DFS in the intention-to-treat population. The OS and safety were secondary endpoints.

Between 1 August 2005 and 24 October 2010, the study team recruited 2056 patients. After a median follow-up of 11.7 years (IQR 9.5-13.1), 262 of 1030 patients (25%) in the control arm and 212 of 1026 patients (21%) in the extended arm experienced a DFS event. The 12-year DFS was 62% (95% confidence interval [CI] 57-66) in the control arm and 67% (95% CI 62-71) in the extended arm (hazard ratio [HR] 0.78, 0.65-0.93; p = 0.006).

Extended-Adjuvant-Treatment-with-Letrozole-Results-in-Longer-Survival-in-Postmenopausal-Patients-with-Breast-Cancer

Disease-free survival (DFS) with median follow-up of 11.7 years.

© Lucia del Mastro

The effect did not change in a multivariate Cox model including nodal status, tumour size, grading, age, HR status, HER2 status, previous chemotherapy, and BMI (p = 0·014).

In total, 263 deaths (13%) occurred, 147 in the control arm and 116 in the extended arm. The 12-year OS was 84% (95% CI 82-87) in the control arm and 88% (95% CI 86-90) in the extended arm (HR 0.77, 0.60-0.98; p = 0.036).

In terms of side effects, arthralgia (31% vs 38%), myalgia (8% vs 12%), hypertension (1% vs 2%) and osteoporosis (5% vs 8%) were significantly more frequent in the extended arm.

The authors concluded that extended adjuvant treatment with 5 years of letrozole resulted in a significant and clinically meaningful improvement in DFS and OS.

The study results were simultaneously published in The Lancet Oncology.

Dr. Monica Arnedos of the Breast Unit, Institut Bergonié in Bordeaux, France who discussed the implications of the study results said that the study adds additional evidence to support extended treatment with aromatase inhibitor in postmenopausal patients, notably after 2-3 years of adjuvant tamoxifen even in clinically low-risk patients for a total duration of 7 to 8 years of endocrine treatment. However, long-term follow-up data from this study is awaiting and it is needed to better define population benefiting from extended treatment.

The study was funded by Novartis and Italian Ministry of Health.

References

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Making Important Decisions During Cancer: A Survivor’s Story

Bethany Hart lives with her husband Kevin, sons, and 3 dogs in the suburbs of Indianapolis, Indiana. She is a survivor of small cell neuroendocrine cervical cancer....

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

October 26, 2021, by NCI Staff Atezolizumab (Tecentriq) is approved as an additional treatment for some patients with stage II to IIIA (pictured) non-small cell...

Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation

Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were...

Teacher Reads To Students One Day After Having Brain Surgery

Meucci - who had her surgery on a Wednesday - was going live from her intensive care unit hospital room that very next Thursday...

6 things you need to know about cervical screening

This article was originally published in 2017 during Cervical Screening Awareness Week. It has now been reviewed and updated. Cervical screening, also known as the...

EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan

On 14 October 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...